DelMar Pharmaceuticals to Present at the 11th Biennial Ovarian Cancer Research Symposium

VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 11, 2016 /PRNewswire/ — DelMar Pharmaceuticals (NASDAQ:DMPI), today announced that the Company and its collaborators from theUniversity of Texas MD Anderson Cancer Center have accepted an invitation to present at the 11^th Biennial Ovarian Cancer Research Symposium to be held at the Rivkin Center for Ovarian Cancer in Seattle, Washington on September 12– 13, 2016.
DelMar will present an abstract “Activity of dianhydrogalactitol (VAL-083) in ovarian tumor models, sensitive or resistant to cisplatin” at a poster session that will take place Monday, September 12th from 5:30-8:00 PM PDT.
VAL-083 is a “first-in-class” small-molecule chemotherapeutic that demonstrated clinical activity against a range of cancers including lung, brain, cervical, ovarian tumors and leukemia both as a single-agent and in combination with other treatments.
In April 2016, the FDA Office of Orphan Products Development (OOPD) granted orphan drug designation for VAL-083 in the treatment of ovarian cancer. The investigational drug candidate had earlier received an orphan designation for glioma and medulloblastoma in the United States and for glioma in Europe.
Connect with DelMar Pharmaceuticals (NASDAQ:DMPI) to receive an Investor Presentation.